Limb-girdle muscular dystrophy type 2I (LGMD2I)
Clinical trials for Limb-girdle muscular dystrophy type 2I (LGMD2I) explained in plain language.
Never miss a new study
Get alerted when new Limb-girdle muscular dystrophy type 2I (LGMD2I) trials appear
Sign up with your email to follow new studies for Limb-girdle muscular dystrophy type 2I (LGMD2I), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for rare muscle disease: new drug enters final testing phase
Disease control OngoingThis study tests a drug called BBP-418 (Ribitol) in 81 people aged 12 to 60 with limb girdle muscular dystrophy type 2I (LGMD2I), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo for 36 months to see if it slows the di…
Matched conditions: LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2I (LGMD2I)
Phase 3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Hope for muscle strength: experimental drug tested for Long-Term use in rare muscular dystrophy
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called BBP-418 (ribitol) in people with limb-girdle muscular dystrophy type 2I/R9, a rare genetic muscle-weakening disease. Participants who completed a previous study will take BBP-418 orally twice d…
Matched conditions: LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2I (LGMD2I)
Phase 3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC